
News & Information
WEIGHT LOSS MEDICATIONS & EXERCISE GLP-1 Receptor Agonists (GLP-1RAs)
What are GLP-1RAs?
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of medications initially developed for type 2 diabetes management that have become widely prescribed for weight management and cardiometabolic risk reduction.
Common versions of these medications include:
Semaglutide (Wegovy and Ozempic)
Liraglutide (Saxenda)
Tirzepatide (Mounjaro): dual GIP and GLP-1 receptor agonist
These medications mimic the pathways of glucagon-like peptide-1 (GLP-1), a hormone naturally produced in the intestines in response to eating food. Unlike the natural hormone, which breaks down within minutes, these medications are formulated so that their action lasts much longer. Their mechanism of action includes:
Stimulating insulin release: When blood sugar rises after a meal, GLP-1RAs tell the pancreas to release more insulin to help cells absorb sugar from the blood.
Suppressing glucagon release: Glucagon is a hormone that normally tells the liver to release stored glucose into the bloodstream. Lowering glucagon helps prevent blood sugar from spiking.
Slowing gastric emptying: By slowing digestion, GLP-1RAs flatten post-meal blood sugar surges.
Increasing satiety and appetite suppression: GLP-1RAs act on areas of the central nervous system and brain that regulate hunger and fullness, signalling that you are full and reducing cravings.
These medications have been shown to work effectively, with reductions of 15% to 20%+ of total body weight being demonstrated alongside meaningful reductions in blood pressure, triglycerides, HbA1c, and circulating liver enzymes. However, treatment can come with side effects and challenges, including:
Gastrointestinal symptoms
Nutritional deficiencies due to reduced food intake
Muscle, strength, and bone loss associated with rapid weight reduction.
High discontinuation rates
Rapid weight rebound following cessation of the medication.
What is the Role of Lifestyle Change?
The objective of weight loss treatment should not simply be to achieve a lower number on the scales. We also need to consider what is happening to muscle mass, body composition, strength, physical function, and metabolic and cardiovascular health.
Current data indicates that approximately 50% of individuals discontinue treatment within 12 months, triggering rapid rebound weight gain at an average rate of 0.4 kg per month. This can result in an average of 60% of the lost weight being put back on in the first year after medication cessation. Additionally, health markers such as blood pressure, cholesterol and HbA1c may return to pre-GLP-1 therapy levels within 1.5 to 2 years.
Current best evidence demonstrates that pairing the use of GLP-1RAs with nutrition and exercise strategies results in greater and more sustained weight loss, along with improved cardiometabolic health.
Role of Nutrition
Appropriate nutritional strategies can help manage gastrointestinal side effects, experienced by up to 75% of individuals. These side effects include nausea, vomiting, diarrhoea, constipation, reflux, or abdominal pain, which can impair tolerance and reduce food and fluid intake. Additionally, appetite suppression and significant calorie deficits frequently lead to inadequate protein and micronutrient intake (calcium, iron, magnesium, fibre, and vitamins A, C, D, and E). Over 20% of patients develop diagnosed deficiencies within 12 months.
Role of Exercise
Exercise, particularly resistance training, is increasingly viewed as a key component of the broader GLP-1RA care pathway. Resistance training is the most potent physiological stimulus for preserving skeletal muscle mass and muscular strength during calorie restriction. Exercise also acts to maintain metabolic health and to break the cycle of post-cessation weight rebound.
When in a calorie deficit, the body catabolises (breaks down to use for energy) both fat and skeletal muscle tissue. Adding mechanical loading through appropriate resistance training stimulates muscle protein synthesis and bone strength, preserving muscle and shifting weight loss more towards adipose (fat) tissue.
Left unchecked, between 15% and 40% of total weight lost on GLP-1RAs can come from lean body mass (including skeletal muscle), alongside reductions in bone mineral density. Why is this important?
Glucose regulation
Muscle mass accounts for approximately 80% of insulin-stimulated glucose uptake, helping to control the amount of blood glucose circulating in our system.
Metabolic rate
Reduced muscle mass lowers resting metabolic rate (the amount of energy we burn at rest).

Strength and mobility
Reduced muscle strength reduces functional capacity and increases frailty and falls risk.

Hormonal signalling
Muscle acts as an endocrine organ, releasing signalling molecules (myokines) that regulate systemic energy metabolism.

Let’s take a look at two recent studies that looked into the role of exercise:
Jensen et al. (2024) evaluated what happens when GLP-1RA therapy stops. Adults with obesity were randomised into four groups for one year:
-
a daily GLP-1RA dose (liraglutide 3.0 mg)
-
exercise (two supervised and two independent sessions per week)
-
a combination of the GLP-1RA dose and exercise placebo.
After one year, all medications and formal exercise supervision ceased. Participants were then followed for an additional 52 weeks where no treatment or intervention was offered.
The trial revealed that relying solely on medication resulted in rapid weight rebound, with participants in the GLP-1RA-only group regaining 6.0 kg more weight than those in the structured exercise group during the off-treatment year. The researchers noted that participants in the structured exercise group fostered positive exercise habits that persisted long after the supervised sessions ended.
Green et al. (2026) focused specifically on the effects of resistance training on weight loss and strength in individuals using tirzepatide (Mounjaro). Participants were divided into two groups for 40 weeks:
-
Mounjaro + supervised resistance training (three sessions per week)
-
Mounjaro + usual activities.
Both groups lost a significant amount of weight (22 kg on average). The resistance training group lost approximately 25% less lean tissue than those not undertaking structured resistance training.
Participants in the non-training group lost nearly 5 kg of lean soft tissue mass. Approximately 2.5 kg of that was lost from muscle in the arms and legs, which equates to a decade or more of age-related muscle decline.
Additionally, those in the training group actually improved strength by 10–15%, whereas the unsupervised group lost strength by 6–9%.
Practical Takeaways
To achieve the best long-term outcomes, individuals should prioritise:

Early resistance training
Engage in structured strength training at least two to three times per week from the outset of treatment to preserve lean tissue, protect bone density, and build functional strength.
Targeted nutrition
Prioritise adequate daily protein, dietary fibre, fluids, and micronutrient-dense foods to counteract reduced appetite, manage gastrointestinal side effects, and prevent deficiencies.
Long-term habit formation
Use the window of reduced appetite while on medication to establish sustainable eating and physical activity routines, reducing the risk of rapid weight rebound if therapy is discontinued.
How a Clinical Exercise Physiologist Can Help
Working alongside a Clinical Exercise Physiologist (CEP) can make this transition safer and more effective. Because many individuals prescribed GLP-1RAs also manage health comorbidities, musculoskeletal conditions, or low baseline conditioning, a generic gym programme is rarely appropriate.
During GLP-1RA-assisted weight loss, a CEP’s role is to deliver individualised, progressive exercise—particularly resistance training—designed to preserve muscle mass, strength, physical function, and metabolic health as weight is lost.
Specifically, a CEP will:
Assess functional capacity and baseline strength to establish a safe entry point to exercise
Prescribe individualised exercise
Monitor tolerance and progress
Support long-term behaviour change
Vitruvian Exercise Physiology
References
Budini et al. (2026). Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression. eClinicalMedicine
Butsch et al. (2025). Nutritional deficiencies and muscle loss in adults with type 2 diabetes using GLP-1 receptor agonists: A retrospective observational study. Obesity Pillars
Exercise & Sports Science Australia & Dietitians Australia. (2026). Joint Submission: PBAC advice on equitable access to GLP-1 medicines through the PBS for the treatment of obesity
Green et al. (2026). Resistance exercise to attenuate lean mass loss during tirzepatide therapy for obesity: a randomized controlled trial. Nature Medicine
Jensen et al. (2024). Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial. eClinicalMedicine
Lundgren et al. (2021). Healthy weight loss maintenance with exercise, liraglutide, or both combined. New England Journal of Medicine
Moiz et al. (2025). Efficacy and safety of glucagon-like peptide-1 receptor agonists for weight loss among adults without diabetes: a systematic review of randomized controlled trials. Annals of Internal Medicine
National Institute for Health and Care Excellence (NICE). (2025). Overweight and obesity management (NICE Guideline)
West et al. (2026). Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ
Wilding, J. P. H., Batterham, R. L., Davies, M., et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553–1564.
Wu, H., Yang, W., Guo, T., Cai, X., & Ji, L. (2025). Trajectory of the body weight after drug discontinuation in the treatment of anti-obesity medications. BMC Medicine, 23(1), 398.
